Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla C Dubinsky

Showing results (211-220 of 286) with videos related to

Pageof 29
Sort By:
Crohn'S & Colitis 360|February 13, 2023
Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBDBenjamin Click, Edward L Barnes, Benjamin L Cohen, et al.
Inflammatory Bowel Diseases|April 23, 2016
TNFRSF1B Is Associated with ANCA in IBDDalin Li, Mark S Silverberg, Talin Haritunians, et al.
Inflammatory Bowel Diseases|March 11, 2011
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behaviorGary R Lichtenstein, Stephan R Targan, Marla C Dubinsky, et al.
Journal of Crohn'S & Colitis|May 16, 2019
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel DiseaseRyan C Ungaro, Andres Yarur, Jacqueline Jossen, et al.
Inflammatory Bowel Diseases|July 22, 2024
Risankizumab Is Effective for The Management of Crohn's Disease of the PouchMaia Kayal, Elizabeth A Spencer, Matthew Smyth, et al.
Inflammatory Bowel Diseases|January 4, 2019
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative ColitisMatthew C Choy, Dean Seah, David M Faleck, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Inflammatory Bowel Diseases|September 19, 2025
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and ChallengesVipul Jairath, Shashi Adsul, Mariangela Allocca, et al.
Diseases of the Colon and Rectum|September 25, 2021
Slow and Steady Wins the Race: A Solid Case for a 3-Stage Approach in Ulcerative ColitisMichael C Plietz, Maia Kayal, Anam Rizvi, et al.
Journal of Crohn'S & Colitis|June 22, 2024
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical TrialsCorey A Siegel, Victoria Rai, An Outtier, et al.
Pageof 29

Showing results (211-220 of 286) with videos related to

Sort By:
Pageof 29
Crohn'S & Colitis 360|February 13, 2023
Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBDBenjamin Click, Edward L Barnes, Benjamin L Cohen, et al.
Inflammatory Bowel Diseases|April 23, 2016
TNFRSF1B Is Associated with ANCA in IBDDalin Li, Mark S Silverberg, Talin Haritunians, et al.
Inflammatory Bowel Diseases|March 11, 2011
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behaviorGary R Lichtenstein, Stephan R Targan, Marla C Dubinsky, et al.
Journal of Crohn'S & Colitis|May 16, 2019
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel DiseaseRyan C Ungaro, Andres Yarur, Jacqueline Jossen, et al.
Inflammatory Bowel Diseases|July 22, 2024
Risankizumab Is Effective for The Management of Crohn's Disease of the PouchMaia Kayal, Elizabeth A Spencer, Matthew Smyth, et al.
Inflammatory Bowel Diseases|January 4, 2019
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative ColitisMatthew C Choy, Dean Seah, David M Faleck, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Inflammatory Bowel Diseases|September 19, 2025
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and ChallengesVipul Jairath, Shashi Adsul, Mariangela Allocca, et al.
Diseases of the Colon and Rectum|September 25, 2021
Slow and Steady Wins the Race: A Solid Case for a 3-Stage Approach in Ulcerative ColitisMichael C Plietz, Maia Kayal, Anam Rizvi, et al.
Journal of Crohn'S & Colitis|June 22, 2024
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical TrialsCorey A Siegel, Victoria Rai, An Outtier, et al.
Pageof 29